1. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
- Author
-
Raimon Sanmartí, Jesús Sanz-Sanz, Rosario García-Vicuña, Benito Dorantes-Calderón, Carmen Martinez-Fernandez, Paloma Vela, Isidoro González-Álvaro, José Andrés Román Ivorra, José Luis Poveda-Andrés, Olatz Ibarra-Barrueta, Santiago Muñoz-Fernández, Emilio Martín-Mola, Blanca Hernández-Cruz, Alberto Morell-Baladrón, Alicia Herrero-Ambrosio, Emilio Monte-Boquet, Francisco Javier de Toro-Santos, [Gonzalez-Alvaro, Isidoro, Garcia-Vicuna, Rosario] Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa, Rheumatol Serv, Madrid 28006, Spain, [Herrero-Ambrosio, Alicia] IdiPaz, Hosp Univ La Paz, Hosp Pharm Serv, Madrid, Spain, [Martin-Mola, Emilio] Univ Autonoma Madrid, IdiPaz, Hosp Univ La Paz, Rheumatol Serv, Madrid, Spain, [Morell-Baladron, Alberto] Hosp Univ La Princesa, Hosp Pharm Serv, Madrid 28006, Spain, [Sanz-Sanz, Jesus] Hosp Puerta de Hierro, Rheumatol Serv, Madrid, Spain, and [Munoz-Fernandez, Santiago] Univ Europea Madrid, Hosp Univ Infanta Sofia, Rheumatol Serv, Madrid, Spain
- Subjects
Optimization ,rheumatoid arthritis ,medicine.medical_specialty ,bDMARD ,Delphi method ,Dose reduction ,Pharmacy ,Biologics ,Arthritis, Rheumatoid ,Psoriatic arthritis ,Tratamiento médico ,Rheumatology ,Risk–benefit ratio ,Internal medicine ,ankylosing spondylitis ,medicine ,Humans ,Pharmacology (medical) ,Spondylitis, Ankylosing ,biologics ,Hospital pharmacy ,Rheumatoid arthritis ,risk/benefit ratio ,Intensive care medicine ,psoriatic arthritis ,Ankylosing spondylitis ,Biological Products ,Medicamento ,Dose-Response Relationship, Drug ,business.industry ,Arthritis, Psoriatic ,Sociedad Española de Farmacia Hospitalaria ,Clinical Science ,medicine.disease ,Ankylosing spondolytis ,Systematic review ,dose reduction ,Sociedad Española de Reumatología ,Physical therapy ,cDMARD ,business ,Enfermedad ,optimization ,Reumatismo ,Risk/benefit ratio - Abstract
The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases Sociedad Española de Reumatología 4.524 JCR (2015) Q1, 6/32 Rheumatology UEM
- Published
- 2014